HeartBeam Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

HeartBeam has a total shareholder equity of $8.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $10.1M and $1.4M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$9.16m
Aandelen	US$8.71m
Totaal verplichtingen	US$1.42m
Totaal activa	US$10.13m

Recente financiële gezondheidsupdates

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

Sep 19

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

Jan 17

Recent updates

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

Sep 28

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Sep 15

HeartBeam GAAP EPS of $0.43 beats by $0.70

Aug 11

HeartBeam: Cardiovascular Diagnostics On The Go

Dec 14

Analyse van de financiële positie

Kortlopende schulden: BEAT's short term assets ($9.7M) exceed its short term liabilities ($1.4M).

Langlopende schulden: BEAT has no long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BEAT is debt free.

Schuld verminderen: BEAT had no debt 5 years ago.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: BEAT has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: BEAT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 54.5% each year

HeartBeam Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

Recent updates

HeartBeam, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

New major risk - Financial position

HeartBeam, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Price target decreased by 38% to US$5.00

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

HeartBeam, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 38% to US$5.00

High number of new and inexperienced directors

HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG

HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology

HeartBeam, Inc. to Report Q4, 2023 Results on Mar 20, 2024

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product

HeartBeam, Inc. Appoints Michael R. Jaff to the Board of Directors

Less than half of directors are independent

Heartbeam Appoints Ken Nelson and Mark Strome to the Board of Directors

HeartBeam, Inc., Annual General Meeting, Jul 07, 2023

HeartBeam, Inc. Announces Automated Cardiac Detection Patent Granted for Heartbeam Aimigo™ System

HeartBeam, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

HeartBeam, Inc. Appoints Robert Eno as President

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

HeartBeam Receives European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. Announces Patent for 12-Lead Electrocardiogram Smartwatch-Based Monitor

Less than half of directors are independent

HeartBeam, Inc. to Report Q3, 2022 Results on Nov 10, 2022

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam gets a new chief medical officer

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

Heartbeam Grants Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Heartbeam Announces FDA Submission of Heartbeam Aimi™ Product

Heartbeam, Inc. Announces Resignation of Alan Baumel as Chief Operating Officer, Effective on August 15, 2022

HeartBeam GAAP EPS of $0.43 beats by $0.70

HeartBeam, Inc. Announces the Appointment of Ken Persen to the Role of Chief Technology Officer

HeartBeam, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HeartBeam, Inc., Annual General Meeting, Jun 15, 2022

No independent directors

HeartBeam, Inc. Announces Board Changes

HeartBeam: Cardiovascular Diagnostics On The Go

Director exercised options to buy US$1.4m worth of stock.

No independent directors

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven